CTRI/2017/07/009024尚未招募未知
Profiling the incidence of ROS1 alteration discovered in human Non Small Cell Lung Cancer
Tata Memorial center0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1)Male or female patients aged >=18 years and < 65 years.
- •2)Histologically confirmed Non Small Cell Lung (NSCLC) Adenocarcinoma.
- •3)Tissue available for analysis.
- •4)Treatment naïve patients.
排除标准
- •1)Patient unable to give consent.
- •2)Patients with Squamous Non-Small Cell Lung Cancer, small cell or large cell cancer.
- •3)Tumor tissue samples older than 5 year period or samples not properly stored.
- •4)Insufficient tissue samples with less tumor cells & high amount of necrosis.
研究者
相似试验
进行中（未招募）
1 期
eoadjuvant study of targeting ROS1 in combination with endocrine therapy in invAsive Lobular carcINoma of the breastEUCTR2019-004942-14-BEInstitut Jules Bordet50
进行中（未招募）
2 期
Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)Invasive Lobular Breast CarcinomaER+ Breast CancerHER2-negative Breast CancerNCT04551495Jules Bordet Institute65
招募中
不适用
Real-world outcome of crizotinib in ROS1-rearranged non-small cell lung cancer patientsKCT0005014Asan Medical Center30
已完成
不适用
Observational biomarker study related to the resistance mechanism of 3rd generation EGFR-TKI (osimertinib)(LOGIK1607)JPRN-UMIN000025290Clinical Research Support Center Kyushu40
进行中（未招募）
1 期
Phase II study of crizotinib and Fluvestrant in lobular breast cancer or diffuse gastric cancerEUCTR2017-001680-20-GBRoyal Marsden Hospital58